KPC Pharmaceuticals,Inc. Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Jan '21 Jan 1, 2021
Cash & Equivalents	794.04	2,271	1,500	1,658	1,574	1,485
Trading Asset Securities	1,965	471.28	603.8	319.4	160.5	334.76
Cash & Short-Term Investments	2,759	2,742	2,103	1,978	1,735	1,820
Cash Growth	37.11%	30.36%	6.35%	14.01%	-4.68%	22.80%
Accounts Receivable	3,271	3,855	3,225	2,625	2,011	1,551
Other Receivables	135.38	123.73	797.75	95.1	169.09	150.59
Receivables	3,407	3,979	4,022	2,720	2,180	1,702
Inventory	1,430	1,540	1,772	1,681	1,884	1,718
Other Current Assets	364.61	294.82	250.14	388.21	381.96	320.86
Total Current Assets	7,961	8,555	8,148	6,766	6,180	5,560
Property, Plant & Equipment	1,237	1,286	1,307	1,291	1,361	1,428
Long-Term Investments	368	305.46	319.61	320.61	278.24	241.55
Goodwill	1,503	1,503	1,503	91.73	91.73	91.73
Other Intangible Assets	373.58	412.22	441.97	355.98	408.88	369.04
Long-Term Deferred Tax Assets	234.32	258.28	269.12	245.6	233.83	236.74
Long-Term Deferred Charges	266.96	237.84	237	199.07	274.49	247.86
Other Long-Term Assets	61.57	53.12	69.83	161.17	64.98	37.13
Total Assets	12,006	12,611	12,295	9,432	8,893	8,213
Accounts Payable	653.97	1,056	936.78	977.12	1,239	821.45
Accrued Expenses	278.69	1,831	1,597	1,262	1,117	1,137
Short-Term Debt	852.54	658.04	725.49	912.76	641.75	627.81
Current Portion of Long-Term Debt	105.79	61.05	1	99.5	0.2	0.2
Current Portion of Leases	-	19.28	22.46	22.57	36.07	22.43
Current Income Taxes Payable	136.24	158.94	149.75	78.76	93.28	78.8
Current Unearned Revenue	61.01	83.32	102.63	186.37	74.09	82.3
Other Current Liabilities	2,036	1,624	329.7	350.01	284.76	379.43
Total Current Liabilities	4,124	5,491	3,865	3,889	3,485	3,149
Long-Term Debt	686.64	46.05	107.56	60	99.5	99.7
Long-Term Leases	48.36	48.59	44.24	44.77	50.47	68.1
Long-Term Unearned Revenue	243.27	229.92	224.09	207.58	245.34	273.58
Long-Term Deferred Tax Liabilities	22.52	21.65	24.28	10.64	15.42	18.39
Other Long-Term Liabilities	25.75	28.03	75.97	77.58	56.67	1.05
Total Liabilities	5,150	5,865	4,341	4,289	3,953	3,610
Common Stock	756.98	756.98	757.99	758.26	758.26	758.26
Additional Paid-In Capital	520.7	520.62	2,327	1,161	1,169	1,163
Retained Earnings	4,037	3,981	3,490	3,071	2,894	2,561
Treasury Stock	-	-	-10.42	-13.15	-26.3	-26.3
Comprehensive Income & Other	-5.49	-5.29	-1.62	6.3	-11.5	-4.93
Total Common Equity	5,309	5,254	6,562	4,983	4,783	4,451
Minority Interest	1,547	1,493	1,392	159.5	156.98	152
Shareholders' Equity	6,856	6,746	7,954	5,143	4,940	4,603
Total Liabilities & Equity	12,006	12,611	12,295	9,432	8,893	8,213
Total Debt	1,693	833.02	900.74	1,140	828	818.24
Net Cash (Debt)	1,066	1,909	1,203	838.19	906.76	1,002
Net Cash Growth	-11.04%	58.73%	43.47%	-7.56%	-9.49%	14.42%
Net Cash Per Share	1.42	2.53	1.58	1.12	1.20	1.32
Filing Date Shares Outstanding	756.98	756.98	757.11	758.13	758.26	758.26
Total Common Shares Outstanding	756.98	756.98	757.99	758.26	758.26	758.26
Working Capital	3,837	3,064	4,283	2,878	2,695	2,411
Book Value Per Share	7.01	6.94	8.66	6.57	6.31	5.87
Tangible Book Value	3,432	3,338	4,617	4,535	4,283	3,990
Tangible Book Value Per Share	4.53	4.41	6.09	5.98	5.65	5.26
Buildings	-	1,325	1,262	1,137	1,136	1,155
Machinery	-	1,058	1,011	988.66	980.07	884.96
Construction In Progress	-	76.46	100.51	64.65	43.51	75.69

Source: S&P Global Market Intelligence. Standard template. Financial Sources.